Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vimpat
Pharma
UCB's Fintepla shows potential to treat a 3rd epilepsy disorder
A phase 3 trial of UCB's Fintepla, treating patients with the rare epileptic condition, CDKL5 deficiency disorder, has achieved its primary endpoint.
Kevin Dunleavy
Jun 27, 2025 11:28am
UCB pens multiple collabs to boost cluster seizure awareness
Aug 22, 2022 3:00pm
The top 10 drugs losing US exclusivity in 2022
Mar 8, 2022 3:00am
UCB bolsters epilepsy portfolio with Zogenix buy
Jan 19, 2022 11:16am
UCB's Vimpat prevails in patent challenge
Aug 15, 2016 11:43am
